Regenerative tissue grafts and methods of making same
A graft containing a scaffold that includes a matrix in which are positioned mesenchymal progenitor cells (MPCs) has the capacity to substantially improve wound healing, including wounds resulting from injury to nerve, bone and vascular tissue. MPCs can be harvested from debrided muscle tissue following orthopaedic trauma. The traumatized muscle-derived progenitor cells are a readily available autologous cell source that can be utilized to effect or improve wound healing in a variety of therapeutic settings and vehicles.
1. A method of obtaining human mesenchymal progenitor cells from debrided human muscle tissue, comprising:
obtaining a sample of debrided human muscle tissue that has been traumatized by mechanical stress comprising extensive mincing until the sample could pass through the tip of a 25-mL serological pipette to induce the formation of human mesenchymal progenitor cells that are positive for CD105 and CD73, wherein the CD105/CD73 ratio is greater than a CD105/CD73 ratio of bone-marrow derived mesenchymal stem cells; and
isolating said human mesenchymal progenitor cells from the sample, wherein the isolated human mesenchymal progenitor cells are positive for CD105 and CD73, wherein the CD105/CD73 ratio is greater than a CD105/CD73 ratio of human bone-marrow derived mesenchymal stem cells.
2. The method of claim 1 , wherein the mesenchymal progenitor cells express one or more neurotrophic factors.
3. The method of claim 1 , wherein the mesenchymal progenitor cells express one or more neurotrophic factors selected from the group consisting of Brain Derived Neurotrophic Factor (BDNF), Ciliary Neurotrophic Factor (CTNF) and Neurotrophic Factor (NT-3).
4. The method of claim 1 , wherein the mesenchymal progenitor cells also are positive for CD 90.
5. The method of claim 1 , further comprising, prior to the isolating step:
digesting the sample of traumatized tissue in a digestion medium; and
incubating the sample.